Robert Chess - 30 Sep 2025 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Reporting relationship: Director
Issuer ticker: NKTR
Reported as of: 30 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Oct 2025, 19:51:27 UTC
Prior SEC filing: 11 Feb 2025
Next SEC filing: 09 Feb 2026
Source filing: View source filing
Reporting owner signature: Mark A. Wilson, Attorney-in-Fact

Key filing fact

Robert Chess filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 01 Oct 2025.

Key facts

This page summarizes Robert Chess's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Oct 2025, 19:51.

Change

Previous filing in this sequence was filed on 11 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001227886 Primary reporting owner

CHESS ROBERT

Relationship: Director
Address: C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO
Signature: Mark A. Wilson, Attorney-in-Fact
Signature date: 01 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NKTR transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +8,000
Change %
Price: $0.000000
Shares after: 8,000
Date: 30 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $56.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .